Objective—Vascular smooth muscle cell (VSMC) transformation to an osteochondrogenic
phenotype is an initial step toward arterial calcification, which is highly correlated with …

Background The biosafety concern of silica nanoparticles (SiNPs) is rapidly expanding
alongside with its mass production and extensive applications. The cardiovascular effects of …

Objective: Despite the current antiatherosclerotic and antithrombotic therapies, the incidence
of advanced atherosclerosis-associated clinical events remains high. Whether long …

Objective: By binding to its high-affinity receptor FcεR1, IgE activates mast cells,
macrophages, and other inflammatory and vascular cells. Recent studies support an …

Objective—Atherosclerotic coronary artery disease is the leading cause of death worldwide,
and current treatment options are insufficient. Using systems-level network cluster analyses …

Preclinical animal studies are mandatory before new treatments can be tested in clinical
trials. However, their use in developing new therapies for sepsis has been controversial …

Objective: Hyperleptinemia, hallmark of obesity, is a putative pathophysiologic trigger for
atherosclerosis. We previously reported a stimulatory effect of leptin on TSP-1 …

Ongoing studies in many species seek to understand the origins, architecture and
consequences of phenotypic variation under normal and dysfunctional conditions, with the …

Background: The rupture of atherosclerotic plaque contributes significantly to cardiovascular
disease. Plasma concentrations of bilirubin—a byproduct of heme catabolism—inversely …

Objective: Enhanced expression of PAI-1 (plasminogen activator inhibitor-1) has been
implicated in atherosclerosis formation in humans with obesity and metabolic syndrome …